Published in Int J Cancer on September 14, 2011
Mutant p53: One, No One, and One Hundred Thousand. Front Oncol (2015) 1.02
Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther (2012) 0.89
p53 abnormalities and potential therapeutic targeting in multiple myeloma. Biomed Res Int (2014) 0.85
The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells. Endocrinology (2014) 0.84
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Invest New Drugs (2014) 0.83
PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. Oncotarget (2016) 0.82
PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53. Cancer Biol Ther (2015) 0.79
Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage. Oncotarget (2015) 0.79
Zn(II)-curc targets p53 in thyroid cancer cells. Int J Oncol (2015) 0.78
Prima-1 induces apoptosis in bladder cancer cell lines by activating p53. Clinics (Sao Paulo) (2013) 0.77
Type 3 deiodinase: role in cancer growth, stemness, and metabolism. Front Endocrinol (Lausanne) (2014) 0.77
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. Int J Mol Sci (2016) 0.76
Diabetes and cancer. Endocr Relat Cancer (2009) 5.04
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest (2009) 3.55
Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev (2009) 3.53
Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol (2013) 2.80
Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab (2004) 2.71
The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem (2008) 2.20
Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem (2002) 2.15
Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. J Clin Endocrinol Metab (2013) 1.86
Papillary thyroid cancer incidence in the volcanic area of Sicily. J Natl Cancer Inst (2009) 1.80
Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab (2010) 1.79
Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology (2012) 1.69
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res (2005) 1.58
The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocr Rev (2008) 1.52
A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab (2002) 1.44
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leuk Res (2011) 1.42
Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism (2002) 1.40
Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev (2013) 1.39
Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res (2009) 1.37
IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.36
Subclinical hypothyroidism in early childhood: a frequent outcome of transient neonatal hyperthyrotropinemia. J Clin Endocrinol Metab (2002) 1.32
Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol (2013) 1.31
Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab (2004) 1.30
Cancer stem cells and chemosensitivity. Clin Cancer Res (2011) 1.26
Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology (2006) 1.23
Risk factors for congenital hypothyroidism: results of a population case-control study (1997-2003). Eur J Endocrinol (2005) 1.22
Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS One (2011) 1.22
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol (2010) 1.20
HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res (2006) 1.16
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res (2006) 1.15
Longitudinal study of thyroid function in children with mild hyperthyrotropinemia at neonatal screening for congenital hypothyroidism. J Clin Endocrinol Metab (2008) 1.14
Thyroid hemiagenesis: prevalence in normal children and effect on thyroid function. J Clin Endocrinol Metab (2003) 1.14
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis. Leuk Res (2007) 1.13
In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene (2002) 1.12
The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol (2015) 1.06
A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet (2002) 1.05
Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J Clin Endocrinol Metab (2008) 1.05
Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform A. J Biol Chem (2003) 1.04
Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology (2003) 1.01
An ATG repeat in the 3'-untranslated region of the human resistin gene is associated with a decreased risk of insulin resistance. J Clin Endocrinol Metab (2002) 1.00
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood (2005) 0.99
Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab (2011) 0.99
Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis (2003) 0.99
Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab (2012) 0.98
Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. J Clin Endocrinol Metab (2009) 0.98
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica (2011) 0.98
High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) (2005) 0.97
Insulin has multiple antiamyloidogenic effects on human neuronal cells. Endocrinology (2012) 0.96
Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J Pathol (2009) 0.96
Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Endocrinology (2009) 0.96
Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid (2007) 0.95
Diabetes: diabetes therapy and cancer risk. Nat Rev Endocrinol (2009) 0.93
Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology (2004) 0.91
Long-term outcome of patients with insular carcinoma of the thyroid: the insular histotype is an independent predictor of poor prognosis. Cancer (2002) 0.91
Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. J Biol Chem (2007) 0.91
Research resource: New and diverse substrates for the insulin receptor isoform A revealed by quantitative proteomics after stimulation with IGF-II or insulin. Mol Endocrinol (2011) 0.91
Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function. J Biol Chem (2003) 0.91
17beta-estradiol up-regulates the insulin-like growth factor receptor through a nongenotropic pathway in prostate cancer cells. Cancer Res (2007) 0.90
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Acta Oncol (2010) 0.90
Role of cyclic AMP response element-binding protein in insulin-like growth factor-i receptor up-regulation by sex steroids in prostate cancer cells. Cancer Res (2009) 0.90
Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL. PLoS One (2011) 0.90
A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid (2011) 0.90
Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomized controlled crossover trial. Diabetes Metab Res Rev (2015) 0.90
c-Abl and insulin receptor signalling. Vitam Horm (2009) 0.88
Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs. Mol Cancer Ther (2013) 0.88
Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg (2012) 0.88
The p53-homologue p63 may promote thyroid cancer progression. Endocr Relat Cancer (2005) 0.87
p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res (2003) 0.87